Abrdn PLC Bei Gene, Ltd. Transaction History

Abrdn PLC

$51.7 Billion
Q4 2024

A detailed history of Abrdn PLC transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Abrdn PLC holds 14,913 shares of BGNE stock, worth $3.38 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

14,913

Previous 27,919 46.58%

Holding current value

$3.38 Million

Previous $6.27 Million 56.06%

% of portfolio

0.01%

Previous 0.01%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 24, 2025	SELL	$174.72 - $246.04 $2.27 Million - $3.2 Million	-13,006 Reduced 46.58%	14,913 $2.75 Million
Q3 2024 Oct 24, 2024	SELL	$143.93 - $224.51 $741,095 - $1.16 Million	-5,149 Reduced 15.57%	27,919 $6.27 Million
Q2 2024 Aug 09, 2024	BUY	$129.52 - $174.32 $1.55 Million - $2.08 Million	11,930 Added 56.44%	33,068 $4.72 Million
Q4 2023 Jan 31, 2024	BUY	$158.67 - $201.58 $3.12 Million - $3.97 Million	19,677 Added 1346.82%	21,138 $3.81 Million
Q4 2022 Jun 20, 2024	SELL	$125.51 - $229.3 $2.47 Million - $4.51 Million	-19,677 Reduced 93.09%	1,461 $321,000
Q4 2022 Feb 09, 2023	SELL	$125.51 - $229.3 $1.43 Million - $2.61 Million	-11,394 Reduced 88.63%	1,461 $321,000
Q3 2022 Nov 10, 2022	BUY	$131.8 - $202.24 $309,071 - $474,252	2,345 Added 22.31%	12,855 $1.73 Million
Q2 2022 Aug 05, 2022	BUY	$121.11 - $216.05 $728,839 - $1.3 Million	6,018 Added 133.97%	10,510 $1.7 Million
Q1 2022 May 04, 2022	SELL	$146.52 - $269.56 $7,179 - $13,208	-49 Reduced 1.08%	4,492 $847,000
Q4 2021 Feb 08, 2022	BUY	$248.56 - $389.34 $76,059 - $119,138	306 Added 7.23%	4,541 $1.23 Million
Q3 2021 Nov 15, 2021	BUY	$249.6 - $403.14 $57,408 - $92,722	230 Added 5.74%	4,235 $1.54 Million
Q2 2021 Aug 10, 2021	BUY	$292.75 - $367.01 $12,881 - $16,148	44 Added 1.11%	4,005 $1.37 Million
Q1 2021 May 06, 2021	BUY	$260.64 - $382.12 $238,485 - $349,639	915 Added 30.04%	3,961 $1.38 Million
Q4 2020 Feb 10, 2021	SELL	$221.31 - $316.61 $2.51 Million - $3.6 Million	-11,360 Reduced 78.86%	3,046 $787,000
Q3 2020 Oct 21, 2020	BUY	$189.18 - $286.44 $209,233 - $316,802	1,106 Added 8.32%	14,406 $4.13 Million
Q2 2020 Aug 10, 2020	BUY	$123.9 - $195.41 $22,302 - $35,173	180 Added 1.37%	13,300 $2.51 Million
Q1 2020 May 13, 2020	BUY	$121.84 - $173.19 $107,341 - $152,580	881 Added 7.2%	13,120 $1.62 Million
Q4 2019 Feb 18, 2020	SELL	$115.78 - $208.34 $264,209 - $475,431	-2,282 Reduced 15.72%	12,239 $2.03 Million
Q3 2019 Nov 13, 2019	BUY	$120.61 - $148.29 $398,013 - $489,357	3,300 Added 29.41%	14,521 $1.78 Million
Q2 2019 Aug 13, 2019	BUY	$113.99 - $146.86 $102,591 - $132,174	900 Added 8.72%	11,221 $1.39 Million
Q1 2019 May 14, 2019	SELL	$122.82 - $151.83 $23,090 - $28,544	-188 Reduced 1.79%	10,321 $1.36 Million
Q4 2018 Feb 12, 2019	BUY	$107.01 - $175.15 $1.12 Million - $1.84 Million	10,509 New	10,509 $1.45 Million

Others Institutions Holding BGNE

# of Institutions

251

Shares Held

45.6M

Call Options Held

322K

Put Options Held

144K

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $23.5B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Abrdn PLC, based on Form 13F filings with the SEC.

News

Stay updated on Abrdn PLC with notifications on news.

Account